|
|
Volumn 10, Issue 7, 2013, Pages 365-
|
|
From ASCO-targeted therapies: Anti-PD-1 approaches-important steps forward in metastatic melanoma
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
IPILIMUMAB;
MK 3475;
NIVOLUMAB;
PROGRAMMED DEATH 1 RECEPTOR;
UNCLASSIFIED DRUG;
ADVANCED CANCER;
ANTINEOPLASTIC ACTIVITY;
CANCER COMBINATION CHEMOTHERAPY;
DIARRHEA;
DOSE RESPONSE;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG ERUPTION;
DRUG MECHANISM;
DRUG SAFETY;
DRUG TOLERABILITY;
FATIGUE;
HUMAN;
MELANOMA;
METASTATIC MELANOMA;
NONHUMAN;
NOTE;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PROTEIN TARGETING;
PRURITUS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CTLA-4 ANTIGEN;
FEMALE;
HUMANS;
MALE;
MELANOMA;
PROGRAMMED CELL DEATH 1 RECEPTOR;
SKIN NEOPLASMS;
|
|
EID: 84879793249
PISSN: 17594774
EISSN: 17594782
Source Type: Journal
DOI: 10.1038/nrclinonc.2013.98 Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|
